UPDATE: Stifel Upgrades Acadia Pharmaceuticals (ACAD) to Buy; Positive DRP KOL Feedback and MDD Seen as Undervalued Option
Tweet Send to a Friend
(Updated - July 7, 2020 8:15 AM EDT)
Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
